It's very clear that there is some urgency. All the experts have expressed concerns to us around maybe wave two, expressed concerns around the co-determinants of being in winter and the increased risk of spread, and certainly those who are knowledgeable in this space weighed up the benefits and the disadvantages. The disadvantage of not having the Pfizer data through Medsafe and through to the officials to follow normal processes versus the urgency of all these other things around COVID that would increase the risk particularly to the vulnerable, those immunocompromised and older people—weighing all of that up. What we've heard from the experts is that there are merits in progressing without approval from Medsafe and that there are more benefits relying substantively on the international evidence. We've listened. We've heard. We've expressed our concerns and some suggestions as to how this bill could be made better. But, at the end of the day, we've taken the advice of experts and the science and we will be supporting this bill in its final reading here today. Thank you.